This November, the biotech industry faces an awkward decision: Donald Trump, whose policy stances have proven unpredictable; or Hillary Clinton, who can scythe drug company stock prices with a single tweet.
But both candidates agree on one thing: Drugs are too expensive. So whatever the outcome, biotech is preparing for more scrutiny on how it makes its money.
“I actually don’t think it matters who gets elected. Pricing is in the crosshairs,” Mason Tenaglia, vice president at health data company QuintilesIMS, said at a STAT panel discussion Thursday at Biotech Week Boston. “The biggest thing that’s going to happen is there will be more transparency.”
